Chemical structure:

IUPAC name:

(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

CAS number:

461432-26-8

Therapy area:

Anti-diabetic

References:

IH/USP

Status:

Under development

Mechanism of action

At least 90% of the glucose reabsorption in the kidney is carried out by sodium-glucose transport proteins (SGLT2) subtype 2, which dapagliflozin inhibits. When this transporter mechanism is blocked, blood glucose is excreted in the urine. In individuals with poorly managed type 2 diabetes and normal renal function, dapagliflozin at the recommended dose of 10 mg per day decreased HbA1c by 0.54-0.84% in comparison to metformin alone.

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.